Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polaris: Efgartigimod PH20 SC in Autoimmune Encephalitis
jRCT2031260337Phase 2Not yet recruiting
- Sponsor
- argenx
- Start
- Jul 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of efgartigimod alfa + hyaluronidase-qvfc in Autoimmune Encephalitis (AE) (4 arms), sponsored by argenx. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on jRCT2031260337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260337.